BMS-HKU Seminar: R&D China Innovation Proposal Collection Program | 30 Mar, 2:30pm
Date: 30 Mar 2023 (Thu)
Venue: MB142, Main Building (or Zoom available)
- Do you want to get feedback from a multinational pharmaceutical company to polish your research idea?
- Do you want to have deep conversations with top pharmaceutical scientists to find inspiration and spark creativity?
- Do you want to explore research collaboration opportunities with top pharmaceutical scientists?
A global biopharmaceutical company, Bristol Myers Squibb, would like to host a seminar at HKU to introduce its new program for scouting and partnering in early R&D space with HKU.
For more details about the program, please click here:
Feng Bian, Ph.D., Executive Director, Integrative Sciences, China R&D, Bristol Myers Squibb
Dr. Feng Bian is an Executive Director, head of China Integrative Sciences at Bristol Myers Squibb based in Shanghai. She is responsible for scouting and partnering in early R&D space to cultivate strong and in-depth scientific relationships with biotech companies, academic and life science communities with a primary focus on China and nearby regions to access emerging innovative sciences including novel targets, breakthrough technologies, new or highly differentiated discovery molecules, and translational research related platforms.
Before this, Dr. Bian was a Senior Director and China Emerging Science Lead in Pfizer Emerging Science & Innovation (ES&I) of Pfizer Worldwide Research, Development & Medical focusing on China and nearby Asia regions. Prior to Pfizer ES&I, Dr. Bian was a senior investigator in China Novartis Institutes for Biomedical Research and group head of liver pharmacology since 2014 in Shanghai. At Novartis, she was a project leader and also managed liver disease pharmacology platform to deliver data packages for worldwide drug discovery projects. Before Novartis, she was a key scientist participated in setting up JNJ China research labs in 2012, and Associate Director of Biology to manage CROs and academic collaborations as well as internal R&D programs. Dr. Bian began her R&D career in Parke-Davis/Warner-Lambert in US as an in vivo pharmacologist in the Neuroscience Division, and later became a principal scientist in Pfizer’s Neurodegeneration and Psychotherapeutics Unit, contributing to programs like Lyrica®, discovery programs for Alzheimer’s disease, bipolar depression, and dermal fibrosis. Dr. Bian has more than 20 years of expertise in small molecule and biologics drug discovery and her work has enabled several NMEs to reach first in human. Dr. Bian received her Doctorate degree in Biochemistry from The Ohio State University and her Bachelor of Science degree from Nankai University at Tianjin, China.